The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents

Drug News and Perspectives

Volumn 17, Issue 3, 2004, Pages 187-194

  Payne, David J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE DERIVATIVE; ANTIBIOTIC AGENT; BACTERIAL ENZYME; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; IMIDAZOLE DERIVATIVE; ISONIAZID; MEROPENEM; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SB 418011; SB 627696; SB 663042; TEICOPLANIN; TETRACYCLINE; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL METABOLISM; DRUG SCREENING; DRUG SYNTHESIS; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; HAEMOPHILUS INFLUENZAE; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; TRANSPOSON;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; BACTERIA; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; GENOME, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PLASMODIUM FALCIPARUM;

EID: 2942746756     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2004.17.3.829016     Document Type: Review

References (30)

1. Sakaki, H., Oishi, H., Hayashi, T., Matsuura, I., Ando, K. and Sawada, M. Thiolactomycin, a new antibiotic. J Antibiot 1982, 35: 396-400.
2. Miyakawa, S., Suzuki, K., Noto, T., Harada, Y. and Okazaki, H. Thiolactomycin, a new antibiotic IV. Biological properties and chemotherapeutic activity in mice. J Antibiot 1982, 35: 411-9.
3. Hayahsi, T., Yamamoto, O., Sasaki, H., Kawaguchi, A. and Okazaki, H. Mechanism of action of the antibiotic thiolactomycin inhibition of fatty acid synthesis of Escherichia coli. Biochem Biophys Res Commun 1983, 115: 1108-13.
4. Heath, R.J., White, S.W. and Rock, C.O. Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl Microbiol Biotechnol 2002, 58: 695-703.
5. Payne, D.J., Warren, P.V., Holmes D.J., Ji, Y. and Lonsdale, J.T. Bacterial fatty acid biosynthesis: A genomics driven target for antibacterial drug discovery. Drug Discov Today 2001, 6: 537-44.
6. Fleischmann, R.D., Adams, M.D., White, O. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995, 269: 496-512.
7. Heath, R.J. and Rock, C.O. A triclosan-resistant bacterial enzyme. Nature 2000, 406: 145.
8. Marrakchi, H., Dewolf, W.E., Quinn, C. et al. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem J 2003, 15: 1055-62.
9. Marrie, T.J., Peeling, R.W., Fine, M.J., Singer, D.E., Coley, C.M. and Kapoor, W.N. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996, 101: 508-15.
10. Hammershlag, M. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001, 14: 181-6.
11. Chirala, S.S. et al. Animal fatty acid synthase: Functional mapping and cloning and expression of the domain I constituent activities. Proc Natl Acad Sci USA 1997, 94: 5588-93.
12. Chan, P., Macarron, R., Payne, D.J., Zalacain, M. and Holmes, D.J. Novel antibacterials: A genomics approach to drug discovery. Curr Drug Targets Infect Disord 2002, 2: 109-19.
13. Ji, Y., Broskey, J., Payne, D.J., Woodnutt, G., Rosenberg, M. and Burnham, M. Validation of drug target by regulated antisense RNA in Staphylococcus aureus. Am Soc Microbiol 2001.
14. Ward, W.H.J., Holdgate, G.A., Rowsell, S. et al. Kinetic and structural characteristics of the inhibition of enoyl(acyl carrier protein) reductase by triclosan. Biochemistry 1999, 38: 12514-25.
15. Payne, D.J., Miller, W.H., Berry, V. et al. Discovery of a novel and potent class of Fab1 directed antibacterial agents. Antimicrob Agents Chemother 2002, 46: 3118-24.
16. Daines, R.A., Pendrak, I., Sham, K. et al. First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modelling. J Med Chem 2003, 46: 5-8.
17. He, X., Mueller, J.P. and Reynolds, K.A. Development of a scintillation proximity assay for beta-ketoacyl carrier protein synthase III. Anal Biochem 2000, 282: 107-14.
18. Heath, R.J., Yu, Y.-T., Shapiro, M.A., Olson, E. and Rock, C.O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J Biol Chem 1998, 273: 30316-20.
19. McMurry, L.M., Oethinger, M. and Levy, S.B. Triclosan targets lipid synthesis. Nature 1998, 394: 531-2.
20. Greenwood, R.C., Nicholas, R.O., Nwanguma, N., VanAller, G.S., Payne, D.J. and Gentry, D. A microtiter-based macromolecular synthesis assay for assessing the MOA (mode of action) of antibacterial agents against Gram-positive and Gram-negative pathogens. Am Soc Microbiol 101st Gen Meet, Orlando 2001, Poster A-24.
21. Heerding, D.A., Chan, G., Dewolf, W.E. et al. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). Bioorg Med Chem Lett 2001, 11: 2061-5.
22. Seefeld, M.A., Miller, W.H., Newlander, K.A. et al. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-Di-substituted 1,2,3,4-tetrahydropyrido[3,4-b]-indoles as potential antibacterial agents. Bioorg Med Chem Lett 2001, 17: 2241-4.
23. Miller, W.H., Seefeld, M.A., Newlander, K.A. et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J Med Chem 2002, 45: 3246-56.
24. Seefeld, M.A., Miller, W.H., Newlander, K.A. et al. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J Med Chem 2003, 46: 1627-35.
25. Fan, F., Yan, K., Wallis, N.G. et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2002, 46: 3343-7.
26. WHO Tuberculosis Fact Sheet. August 2002, No. 104.
27. Phillipps, R.S. Current status of malaria and potential for control. Clin Microbiol Rev 2001, 14: 208-26.
28. Gornicki, P. Apicoplast fatty acid biosynthesis as a target for medical intervention in api-complexan parasites. Int J Parasitol 2003, 33: 885-96.
29. He, X. and Reynolds, K.A. Purification, characterisation, and identification of novel inhibitors of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus. Antimicrob Agents Chemother 2002, 46: 1310-8.
30. Khandekar, S.S., Gentry, D.R., Van Aller, G.S. et al. Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH). J Biol Chem 2001, 276: 30024-30.